Omecamtiv mecarbil: A new cardiac myosin activator for the treatment of heart failure

Expert Opinion on Investigational Drugs

Volumn 25, Issue 1, 2016, Pages 117-127

  Liu, Licette C Y ^a   Dorhout, Bernard ^a   Van Der Meer, Peter ^a   Teerlink, John R ^b   Voors, Adriaan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiac myosin activator; CK 1827452; heart failure with reduced ejection fraction; omecamtiv mecarbil

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DILTIAZEM; KETOCONAZOLE; OMECAMTIV MECARBIL; PLACEBO; CARDIAC MYOSIN; CARDIOTONIC AGENT; UREA;

ACUTE HEART FAILURE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION TIME; HEART MUSCLE CONTRACTILITY; HEART STROKE VOLUME; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE; THORAX PAIN; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEART CONTRACTION; HEART FAILURE, SYSTOLIC; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CARDIAC MYOSINS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HEART FAILURE, SYSTOLIC; HUMANS; MYOCARDIAL CONTRACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UREA;

EID: 84954389267     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1123248     Document Type: Article

References (32)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: A report from the american heart association. Circulation. 2015 Jan 27;131 (4):e29-322.
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the united states: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;149 (2):209-216.
3. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362 (3):228-238.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2012;14 (8):803-869.
5. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-111.
6. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 1991 Nov 21;325(21):1468-1475.
7. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986;112 (4):787-791.
8. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the flolan international randomized survival trial (FIRST). Am Heart J. 1999;138(1 Pt 1):78-86.
9. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. Jama. 2002 Mar 27;287(12):1541-1547.
10. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 Mar 19;41 (6):997-1003.
11. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202.
12. De Tombe PP. Cardiac myofilaments: Mechanics and regulation. J Biomech. 2003 May;36(5):721-730.
13. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70:23-49.
14. Spudich JA. Hypertrophic and dilated cardiomyopathy: Four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014;106 (6):1236-1249.
15. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18;331 (6023):1439-1443.
16. Malik FI, Morgan BP. Cardiac myosin activation part 1: From concept to clinic. J Mol Cell Cardiol. 2011 Oct;51(4):454-461.
17. Morgan BP, Muci A, Lu PP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett. 2010 Aug 20;1(9):472-477.
18. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010;3(4):522-527.
19. Bakkehaug JP, Kildal AB, Engstad ET, et al. Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity. Circ Heart Fail. 2015;8 (4):766-775.
20. Utter MS, Ryba DM, Li BH, et al. Omecamtiv mecarbil, a cardiac myosin activator, increases Ca2+ sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomyosin E54K. J Cardiovasc Pharmacol. 2015;66(4):347-353.
21. Teerlink JR. A novel approach to improve cardiac performance: Cardiac myosin activators. Heart Fail Rev. 2009 Dec;14 (4):289-298.
22. Liu Y, White HD, Belknap B, et al. Omecamtiv mecarbil modulates the kinetic and motile properties of porcine beta-cardiac myosin. Biochemistry. 2015 Mar 17;54(10):1963-1975.
23. Teerlink JR, Malik FI, Kass DA. Letter by Teerlink et al. regarding article, myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity. Circ Heart Fail. 2015;8(6):1141.
24. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study. Lancet. 2011 Aug 20;378(9792):667-675.
25. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20;378 (9792):676-683.
26. Greenberg BH, Chou W, Saikali KG, et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan;3(1):22-29.
27. Vu T, Ma P, Xiao JJ, et al. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015;55(11):1236-1247.
28. Jerling M, Chew T, Escandon RD, et al. Oral bioavailability of the selective cardiac myosin activator CK-1827452: Chronic oral inotropic therapy for heart failure? J Card Fail. 2007;13(6, Suppl. 2):S148.
29. Cytokinetics provides updates from Phase I clinical trials of CK-1827452 results from three trials support ongoing clinical development program [Internet]. 2008 [cited 2015 Nov 17]. Available from: Http://ir. cytokinetics.com/phoenix.zhtml?c= 142156&p=irol-newsArticle&ID= 1165647.
30. Teerlink JR Chronic oral study of myosin activation to increase contractility in heart failure(COSMIC-HF): Final results from a double-blind, randomized, placebo-controlled, multicenter study. Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions; 2015.
31. Teerlink JR ATOMIC-AHF: Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: Results from ATOMIC-AHF-European Society of Cardiology (ESC) 2013 Congress.
32. Egstrup M, Gustafsson I, Andersen MJ, et al. Haemodynamic response during low-dose dobutamine infusion in patients with chronic systolic heart failure: comparison of echocardiographic and invasive measurements. Eur Heart J Cardiovasc Imaging. 2013;14(7):659-667.